The trend is your friend peeps. Small blips on a day to day level will blend out if you step back see the greater trajectory the company is heading on.
My only concern at this stage is the company being able to prove the efficacy of their treatments versus the control group (i.e. conventional treatment). The market cap will sort itself out and begin to reflect the potential of the company in the coming months (i.e if the sleep apnea trial proves CBDs effectiveness then a big rerate would be expected. If not then we have 3 other trials on the cards and can expect some short term pain that reflects a reduction in upside due to one market opportunity being lost). I believe this risk is largely baked into the current share price and expect consolidation at these levels.
Currently there are 4 material opportunities still on the table that will act as significant price catalysts. In my opinion there aren't many other companies on the ASX currently that offer a decent hedged position like IHL has. Let the trials do the talking and the rest will work itself out.
- Forums
- ASX - By Stock
- IHL
- Ann: Commencement of Phase 2a Sleep Apnoea Clinical Trial
Ann: Commencement of Phase 2a Sleep Apnoea Clinical Trial, page-32
-
- There are more pages in this discussion • 102 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online